Not a stand-alone test for ovarian cancer screening or diagnosis. May be used in the workup for and monitoring of epithelial ovarian cancer post therapy. Not recommended for breast cancer or germ-cell tumors.
Quantitative Electrochemiluminescent Immunoassay
This test is New York DOH approved.
The Roche CA 125 electrochemiluminescent immunoassay is used. Results obtained with different test methods or kits cannot be used interchangeably. The CA 125 test is used as an aid in monitoring response to therapy for patients with epithelial ovarian cancer. Serial testing for patient CA 125 values should be used in conjunction with other clinical methods for monitoring ovarian cancer. Patients with confirmed ovarian carcinoma may have pretreatment CA 125 values in the same range as healthy individuals. Elevations may be observed in patients with nonmalignant disease. Therefore, a CA 125 value, regardless of level, should not be interpreted as absolute evidence of the presence or absence of malignant disease.